H. Lundbeck A/S Stock

Equities

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:39 2024-04-19 am EDT 5-day change 1st Jan Change
32.7 DKK +0.49% Intraday chart for H. Lundbeck A/S -3.54% -0.18%
Sales 2024 * 20.99B 3B Sales 2025 * 21.86B 3.12B Capitalization 31.49B 4.5B
Net income 2024 * 2.98B 426M Net income 2025 * 3.41B 487M EV / Sales 2024 * 1.29 x
Net cash position 2024 * 4.43B 633M Net cash position 2025 * 8.05B 1.15B EV / Sales 2025 * 1.07 x
P/E ratio 2024 *
10.8 x
P/E ratio 2025 *
9.49 x
Employees 5,681
Yield 2024 *
2.71%
Yield 2025 *
3.1%
Free-Float 30.74%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on H. Lundbeck A/S

1 day+0.49%
1 week-3.60%
Current month-1.57%
1 month-0.91%
3 months-5.11%
6 months-14.89%
Current year-0.18%
More quotes
1 week
32.28
Extreme 32.28
33.90
1 month
31.98
Extreme 31.98
34.64
Current year
31.62
Extreme 31.62
36.32
1 year
30.96
Extreme 30.96
39.84
3 years
23.30
Extreme 23.295
39.84
5 years
23.30
Extreme 23.295
39.84
10 years
23.30
Extreme 23.295
39.84
More quotes
Date Price Change Volume
24-04-19 32.7 +0.49% 193,909
24-04-18 32.54 -0.85% 415,250
24-04-17 32.82 -0.55% 218,252
24-04-16 33 -1.49% 483,388
24-04-15 33.5 -1.18% 354,318

Delayed Quote Nasdaq Copenhagen, April 19, 2024 at 10:59 am EDT

More quotes
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
32.7 DKK
Average target price
38.71 DKK
Spread / Average Target
+18.37%
Consensus
  1. Stock Market
  2. Equities
  3. HLUN B Stock